J&J to stop studies of depression drug due to low effectiveness
(Reuters) -Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to ...
J&J to stop late-stage study of add-on depression drug
Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive ...
NBC Connecticut1mon
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...
MarketWatch1mon
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration ... makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least ...